Vaxxinity (VAXX) Competitors $0.01 -0.02 (-60.00%) As of 03:06 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock VAXX vs. ATNF, NRSN, CMMB, IMNN, PASG, HOTH, LEXX, ASBP, BLRX, and SYBXShould you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include 180 Life Sciences (ATNF), NeuroSense Therapeutics (NRSN), Chemomab Therapeutics (CMMB), Imunon (IMNN), Passage Bio (PASG), Hoth Therapeutics (HOTH), Lexaria Bioscience (LEXX), Aspire Biopharma (ASBP), BioLineRx (BLRX), and Synlogic (SYBX). These companies are all part of the "pharmaceutical products" industry. Vaxxinity vs. Its Competitors 180 Life Sciences NeuroSense Therapeutics Chemomab Therapeutics Imunon Passage Bio Hoth Therapeutics Lexaria Bioscience Aspire Biopharma BioLineRx Synlogic 180 Life Sciences (NASDAQ:ATNF) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability. Does the media favor ATNF or VAXX? In the previous week, 180 Life Sciences had 3 more articles in the media than Vaxxinity. MarketBeat recorded 3 mentions for 180 Life Sciences and 0 mentions for Vaxxinity. 180 Life Sciences' average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score. Company Overall Sentiment 180 Life Sciences Neutral Vaxxinity Neutral Do insiders and institutionals have more ownership in ATNF or VAXX? 4.1% of 180 Life Sciences shares are held by institutional investors. Comparatively, 82.9% of Vaxxinity shares are held by institutional investors. 38.2% of 180 Life Sciences shares are held by insiders. Comparatively, 64.1% of Vaxxinity shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is ATNF or VAXX more profitable? Vaxxinity's return on equity of 0.00% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A -141.25% -80.77% Vaxxinity N/A N/A N/A Which has more risk and volatility, ATNF or VAXX? 180 Life Sciences has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Vaxxinity has a beta of -24.16, indicating that its share price is 2,516% less volatile than the S&P 500. Which has better valuation and earnings, ATNF or VAXX? 180 Life Sciences is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/A-$6.17M-$15.07-0.22VaxxinityN/AN/A-$56.93M-$0.45-0.02 SummaryVaxxinity beats 180 Life Sciences on 6 of the 9 factors compared between the two stocks. Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VAXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VAXX vs. The Competition Export to ExcelMetricVaxxinityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.27M$792.99M$5.45B$9.66BDividend YieldN/A4.84%4.60%4.13%P/E Ratio-0.021.1629.8624.63Price / SalesN/A25.59376.0779.59Price / CashN/A19.5624.8428.01Price / Book0.096.558.605.76Net Income-$56.93M-$4.39M$3.26B$266.93M7 Day PerformanceN/A10.31%0.55%0.31%1 Month PerformanceN/A1.18%1.40%0.14%1 Year PerformanceN/A22.76%36.52%22.83% Vaxxinity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VAXXVaxxinityN/A$0.01-60.0%N/A+25.0%$1.27MN/A-0.0290Gap UpATNF180 Life Sciences0.5379 of 5 stars$3.16-6.1%N/A+70.6%$19.15MN/A-0.217News CoverageNRSNNeuroSense Therapeutics2.0533 of 5 stars$1.40+1.1%$14.00+903.6%+91.2%$19.00MN/A-2.5710CMMBChemomab Therapeutics2.1202 of 5 stars$1.01+0.5%$8.50+745.8%+3.9%$18.95MN/A-1.3220IMNNImunon2.6938 of 5 stars$8.52-2.7%$232.50+2,628.9%-56.1%$17.96M$500K-0.4230Analyst UpgradeAnalyst RevisionPASGPassage Bio3.3906 of 5 stars$5.73-1.4%$150.00+2,517.8%-57.2%$17.94MN/A-0.28130Upcoming EarningsHOTHHoth Therapeutics2.3321 of 5 stars$1.34-3.3%$4.00+199.6%+95.1%$17.38MN/A-1.154News CoverageLEXXLexaria Bioscience2.322 of 5 stars$0.86-1.6%$4.00+364.6%-73.0%$17.31M$460K-1.327ASBPAspire BiopharmaN/A$0.35-2.0%N/AN/A$17.17MN/A0.00N/AGap UpBLRXBioLineRx2.203 of 5 stars$3.92+0.6%$26.00+564.1%-88.0%$16.68M$28.94M-0.4440SYBXSynlogic0.9565 of 5 stars$1.42-5.3%N/A-4.1%$16.63M$10K-0.5780Upcoming EarningsGap Down Related Companies and Tools Related Companies 180 Life Sciences Competitors NeuroSense Therapeutics Competitors Chemomab Therapeutics Competitors Imunon Competitors Passage Bio Competitors Hoth Therapeutics Competitors Lexaria Bioscience Competitors Aspire Biopharma Competitors BioLineRx Competitors Synlogic Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VAXX) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access